Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Home
Plasmablastic Lymphoma: 2026 Update On Diagnosis, Risk Stratification, And Management.

Home
Plasmablastic Lymphoma: 2026 Update On Diagnosis, Risk Stratification, And Management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma.

Blood cancer discovery·2026

Same author

A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B-Cell Lymphoma.

American journal of hematology·2026

Same author

Managing cytokine release syndrome in hematological malignancies being treated with CAR-T cell therapy.

Expert review of hematology·2026

Same author

From immunomodulators (IMiDs) to cereblon E3 ligase modulator (CELMoDs): the evolution of cereblon modulators in lymphoma therapy.

Leukemia & lymphoma·2026

Same author

Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study.

Blood·2026

Same author

Zanubrutinib and pirtobrutinib show synergistic killing and suppression of BTK signaling in MYD88-mutated lymphoma cells.

Blood advances·2026

Same journal

Dordaviprone Maintenance After Allogeneic HCT for High-Risk Acute Myeloid Leukemia and Myelodysplastic Neoplasm.

American journal of hematology·2026

Same journal

Early Treatment Failure in Patients Receiving Ciltacabtagene-Autoleucel for Relapsed/Refractory Multiple Myeloma.

American journal of hematology·2026

Same journal

Impact of Atrial Fibrillation on the Risk of Thrombosis and Bleeding for Patients With Polycythemia Vera and Essential Thrombocytosis in the Real World.

American journal of hematology·2026

Same journal

Mosaic Chromosomal Alterations Identify Ultra-High Risk Clonal Hematopoiesis in Patients With Lymphoma Undergoing Intensive Chemotherapy.

American journal of hematology·2026

Same journal

A Multicenter National Study of AL Amyloidosis in China: Insights Into Real-World Diagnosis, Treatment, and Prognosis.

American journal of hematology·2026

Same journal

Extended Cancer Spectrum in Adults With Telomere Biology Disorders: Insights From a 113-Patient Single-Center Cohort.

American journal of hematology·2026

See all related articles

Related Experiment Video

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

Plasmablastic Lymphoma: 2026 Update on Diagnosis, Risk Stratification, and Management.

Jorge J Castillo¹, Brady E Beltrán², Jorge A Florindez³

¹Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.

American Journal of Hematology

|May 15, 2026

View abstract on PubMed

Summary

This summary is machine-generated.

Plasmablastic lymphoma (PBL) is an aggressive cancer with poor prognosis. Current treatments like EPOCH chemotherapy may be improved with targeted therapies and clinical trial participation.

Related Experiment Videos

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

Area of Science:

Hematology
Oncology

Background:

Plasmablastic lymphoma (PBL) is a rare, aggressive, CD20-negative lymphoma.
PBL typically presents with a poor prognosis, especially with standard treatments.
While often associated with HIV and immunosuppression, PBL can occur in immunocompetent individuals.

Purpose of the Study:

To summarize the current understanding of Plasmablastic Lymphoma.
To outline diagnostic criteria and differential diagnoses for PBL.
To review risk stratification, management strategies, and future directions for PBL.

Main Methods:

Diagnostic confirmation relies on clinical suspicion and pathological findings.
Key diagnostic markers include EBV-encoded RNA (EBER) expression and MYC gene rearrangements.
Differential diagnosis involves distinguishing PBL from other lymphomas like EBV+ DLBCL.

Main Results:

Advanced age (≥60 years), advanced stage, and high International Prognostic Index scores correlate with worse survival.
Combination chemotherapy, such as infusional EPOCH, is a recommended treatment.
Emerging therapies including bortezomib, daratumumab, and BCMA-targeted treatments show potential.

Conclusions:

Accurate diagnosis and risk stratification are crucial for managing PBL.
Novel therapeutic approaches and clinical trial enrollment are essential for improving patient outcomes.
Further research into targeted therapies holds promise for treating this aggressive lymphoma.